Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:NBTX NASDAQ:PRAX NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$34.70+0.7%$28.44$13.36▼$40.16$1.12B1.58421,267 shs326,063 shsNBTXNanobiotix$20.97-7.9%$10.60$2.76▼$22.85$1.01B0.723,192 shs121,069 shsPRAXPraxis Precision Medicines$52.04+2.1%$47.45$26.70▼$91.83$1.10B2.62449,392 shs491,763 shsTNYATenaya Therapeutics$1.77+2.9%$1.16$0.36▼$4.01$288.48M3.153.03 million shs4.73 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-1.37%-12.87%+30.04%+88.82%+23.07%NBTXNanobiotix+11.07%+26.42%+166.59%+319.52%+338.92%PRAXPraxis Precision Medicines-6.25%-2.67%+8.82%+9.02%-21.50%TNYATenaya Therapeutics+6.17%+8.86%+27.41%+171.81%-2.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$34.70+0.7%$28.44$13.36▼$40.16$1.12B1.58421,267 shs326,063 shsNBTXNanobiotix$20.97-7.9%$10.60$2.76▼$22.85$1.01B0.723,192 shs121,069 shsPRAXPraxis Precision Medicines$52.04+2.1%$47.45$26.70▼$91.83$1.10B2.62449,392 shs491,763 shsTNYATenaya Therapeutics$1.77+2.9%$1.16$0.36▼$4.01$288.48M3.153.03 million shs4.73 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-1.37%-12.87%+30.04%+88.82%+23.07%NBTXNanobiotix+11.07%+26.42%+166.59%+319.52%+338.92%PRAXPraxis Precision Medicines-6.25%-2.67%+8.82%+9.02%-21.50%TNYATenaya Therapeutics+6.17%+8.86%+27.41%+171.81%-2.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 2.80Moderate Buy$61.5777.44% UpsideNBTXNanobiotix 2.25Hold$11.00-47.54% DownsidePRAXPraxis Precision Medicines 2.75Moderate Buy$85.5664.40% UpsideTNYATenaya Therapeutics 2.71Moderate Buy$6.25253.11% UpsideCurrent Analyst Ratings BreakdownLatest TNYA, DNTH, NBTX, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NBTXNanobiotixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TNYATenaya TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025NBTXNanobiotixHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/18/2025NBTXNanobiotixLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.009/18/2025PRAXPraxis Precision MedicinesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.009/12/2025DNTHDianthus TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $65.009/12/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $44.009/9/2025DNTHDianthus TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$56.00 ➝ $63.009/9/2025DNTHDianthus TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $100.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$4.85M230.10N/AN/A$11.91 per share2.91NBTXNanobiotix$7.16M140.49N/AN/A($1.51) per share-13.89PRAXPraxis Precision Medicines$7.77M141.07N/AN/A$23.90 per share2.18TNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$84.97M-$3.25N/AN/AN/A-2,364.56%-34.72%-32.72%11/6/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/AN/APRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/AN/A-60.07%-54.84%11/5/2025 (Estimated)TNYATenaya Therapeutics-$111.13M-$0.96N/AN/AN/AN/A-93.83%-75.66%11/5/2025 (Estimated)Latest TNYA, DNTH, NBTX, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DNTHDianthus Therapeutics-$0.86-$0.88-$0.02-$0.88$0.87 million$0.19 million8/6/2025Q2 2025TNYATenaya Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A13.1213.12NBTXNanobiotixN/A0.63N/APRAXPraxis Precision MedicinesN/A6.316.31TNYATenaya TherapeuticsN/A6.006.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%NBTXNanobiotix38.81%PRAXPraxis Precision Medicines67.84%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics8.15%NBTXNanobiotix3.45%PRAXPraxis Precision Medicines2.70%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8032.19 million26.86 millionOptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionablePRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableTNYATenaya Therapeutics110162.98 million83.69 millionOptionableTNYA, DNTH, NBTX, and PRAX HeadlinesRecent News About These CompaniesTenaya Therapeutics CEO Faraz Ali to Speak at Upcoming Investor and Industry Conferences in October 2025October 2, 2025 | quiverquant.comQTenaya Therapeutics to Participate in Upcoming October Investor ConferencesOctober 2, 2025 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by AnalystsSeptember 20, 2025 | marketbeat.comTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)September 18, 2025 | globenewswire.comTenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comNuveen LLC Purchases New Shares in Tenaya Therapeutics, Inc. $TNYASeptember 9, 2025 | marketbeat.comTenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2, 2025 | globenewswire.comTenaya Therapeutics Reports Interim Data from Largest Pediatric MYBPC3-Associated HCM Study Highlighting Urgent Need for Novel TherapeuticsAugust 31, 2025 | quiverquant.comQTenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025August 31, 2025 | globenewswire.comTenaya Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comTenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 8, 2025 | globenewswire.comTenaya Therapeutics reports Q2 EPS (14c), consensus (19c)August 7, 2025 | msn.comTenaya (TNYA) Q2 Loss Narrows 59%August 7, 2025 | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comTenaya Therapeutics stock rises after positive safety reviews for heart gene therapiesJuly 30, 2025 | investing.comTenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedJuly 30, 2025 | globenewswire.comTNYA - Tenaya Therapeutics Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMTNYA - Tenaya Therapeutics Inc Trailing Returns - MorningstarJuly 8, 2025 | morningstar.comMTenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNYA, DNTH, NBTX, and PRAX Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$34.70 +0.24 (+0.70%) Closing price 04:00 PM EasternExtended Trading$34.71 +0.01 (+0.03%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Nanobiotix NASDAQ:NBTX$20.97 -1.81 (-7.95%) Closing price 04:00 PM EasternExtended Trading$20.96 -0.01 (-0.03%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Praxis Precision Medicines NASDAQ:PRAX$52.04 +1.06 (+2.08%) Closing price 04:00 PM EasternExtended Trading$52.08 +0.04 (+0.07%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Tenaya Therapeutics NASDAQ:TNYA$1.77 +0.05 (+2.91%) Closing price 04:00 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Dividend Aristocrats to Buy Before Year’s End Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
